В обзоре представлены современные данные о профилактическом действии антиагрегантной и антикоагулянтной терапии плацента-ассоциированных заболеваний. Включена информация из зарубежных и отечественных статей, опубликованных за последние 15 лет в базах данных Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health, CyberLeninka, Pubmed. В последние годы появились сообщения об эффективности низкомолекулярных гепаринов (НМГ) в профилактике плацента-ассоциированных осложнений (ПАО). M. Rodger и соавт. в своем исследовании (2016 г.) рассматривают влияние НМГ на развитие ПАО. Пациентки, предыдущая беременность которых осложнилась преэклампсией или задержкой роста плода, были рандомизированы на 2 группы. 1-я группа беременных начала получать инъекции НМГ на раннем сроке беременности (до 12 нед), 2-я группа не принимала. Таким образом, только у 19[%] женщин, получающих терапию НМГ, и у 43[%] женщин, не принимающих препарат, развились ПАО, что может свидетельствовать об эффективности НМГ. Представленные данные подтверждают актуальность проблемы ПАО, а разработка эффективных методов своевременно начатой профилактики этих заболеваний позволяет улучшить исходы беременности.
Poon LC, Kametas NA, Chelemen T, et al. Maternal risk factors for hypertensive disorders in pregnancy: A multivariate approach. J Hum Hypertens. 2010;24(2):104-10.
Rousso D, Panidis D, Gkoutzioulis F, et al. Effect of the interval between pregnancies on the health of mother and child. Eur J Obstet Gynecol Reprod Biol. 2002;105(1):4-6.
Martin AS, Monsour M, Kawwass JF, et al. Risk of Preeclampsia in Pregnancies After Assisted Reproductive Technology and Ovarian Stimulation. Matern Child Health J. 2016;20(10):2050-6.
Cnattingius S, Bergström R, Lipworth L, Kramer MS. Prepregnancy Weight and the Risk of Adverse Pregnancy Outcomes. N Engl J Med. 1998;338(3):147-52.
Villa PM, Kajantie E, Räikkönen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: A randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 2013;120(1):64-74.
Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 Suppl. 1(Suppl. 1):1-33.
Miranda J, Simões RV, Paules C, et al. Metabolic profiling and targeted lipidomics reveals a disturbed lipid profile in mothers and fetuses with intrauterine growth restriction. Sci Rep. 2018;8(1):13614.
Ferrazzi E, Bozzo M, Rigano S, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol. 2002;19(2):140-6.
Baschat AA, Kush M, Berg C, et al. Hematologic profile of neonates with growth restriction is associated with rate and degree of prenatal Doppler deterioration. Ultrasound Obstet Gynecol. 2013;41(1):66-72.
Figueras F, Gratacos E. Stage-based approach to the management of fetal growth restriction. Prenat Diagn. 2014;34(7):655-9.
Snijders RJ, Sherrod C, Gosden CM, Nicolaides KH. Fetal growth retardation: Associated malformations and chromosomal abnormalities. Am J Obstet Gynecol. 1993;168(2):547-55.
Anandakumar C, Chew S, Wong YC, et al. Early asymmetric IUGR and aneuploidy. J Obstet Gynaecol Res. 1996;22(4):365-70.
Soong YK, Wang TH, Lee YS, Chen CP. Genome-Wide Detection of Uniparental Disomy in a Fetus with Intrauterine Growth Restriction Using Genotyping Microarrays. Taiwan J Obstet Gynecol. 2009;48(2):152-8.
ACOG Practice Bullettin No 204: Fetal growth restriction. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins – Obstetrics and the Society forMaternal-FetalMedicin. Obstet Gynecol. 2019;133(2):e97-e109.
Khan NA, Kazzi J. Yield and costs of screening growth-retarded infants for torch infections. Am J Perinatol. 2000;17(3):131-5.
Walker PG, ter Kuile FO, Garske T, et al. Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: A modelling study. Lancet Glob Health. 2014;2(8):e460-7.
Lewi L, Gucciardo L, Huber A, et al. Clinical outcome and placental characteristics of monochorionic diamniotic twin pairs with early- and late-onset discordant growth. Am J Obstet Gynecol. 2008;199(5):511.e1-7.
Whigham CA, MacDonald TM, Walker SP, et al. The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development. Placenta. 2019;84:28-31.
Zhong Y, Zhu F, Ding Y. Serum screening in first trimester to predict pre-eclampsia, small for gestational age and preterm delivery: Systematic review and meta-analysis. BMC Pregnancy Childbirth. 2015;15:191.
Proctor LK, Toal M, Keating S, et al. Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2009;34(3):274-82.
Gaccioli F, Sovio U, Cook E, et al. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study. Lancet Child Adolesc Health. 2018;2(8):569-81.
Method for predicting the risk of development of pre-eclampsia in women of different somatotypes 2018;19:1-16.
Наволоцкая В.К., Ляшко Е.С., Шифман Е.М., и др. Возможности прогнозирования осложнений преэклампсии (обзор литературы). Проблемы репродукции. 2019;25(1):87-96 [Navolotskaia VK, Liashko ES, Shifman EM, et al. Vozmozhnosti prognozirovaniia oslozhnenii preeklampsii (obzor literatury). Problemy reproduktsii. 2019;25(1):87-96 (in Russian)].
Berbets A, Koval H, Barbe A, et al. Melatonin decreases and cytokines increase in women with placental insufficiency. J Matern Neonatal Med. 2021;34(3):373-8.
Berbets A, Barbe AM, Andriiets OA, et al. Melatonin Levels Decrease in the Umbilical Cord in Case of Intrauterine Growth Restriction. Med Life. 2020;13(4):548-53.
Fowden AL, Forhead AJ. Endocrine mechanisms of intrauterine programming. Reproduction. 2004;127(5):515-26.
Carver TD, Anderson SM, Aldoretta PW, et al. Glucose suppression of insulin secretion in chronically hyperglycemic fetal sheep. Pediatr Res. 1995;38(5):754-62.
Hill JM, Agoston DV, Gressens P, McCune SK. Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain: Relation to ontogenic events. J Comp Neurol. 1994;342(2):186-205.
Murphy VE, Smith R, Giles WB, Clifton VL. Endocrine regulation of human fetal growth: The role of the mother, placenta, and fetus. Endocr Rev. 2006;27(2):141-69.
Wat JM, Audette MC, Kingdom JC. Molecular actions of heparin and their implications in preventing pre-eclampsia. J Thromb Haemost. 2018;16(8):1510-22.
Medvedev BI, Syundyukova EG, Sashenkov SL. Possibilities of preeclampsia prevention. Modern problems of science and education. 2017;2.
Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016;388(10060):2629-41.
Mello G, Parretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45(1):86-91.
Haddad B, Winer N, Chitrit Y, et al. Enoxaparin and Aspirin Compared with Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications. Obstet Gynecol. 2016;128(5):1053-63.
Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol. 2017;216(3):296.e1-296.e14.
Costantine MM, Cleary K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013;121(2 Pt 1):349-53.
Yu CKH, Sykes L, Sethi M, et al. Vitamin D deficiency and supplementation during pregnancy. Clin Endocrinol (Oxf). 2009;70(5):685-90.
Owens NJ. Vitamin D supplementation for women during pregnancy: Summary of a Cochrane review. Explore (NY). 2020;16(1):73-4.
Achamrah N, Ditisheim A. Nutritional approach to preeclampsia prevention. Curr Opin Clin Nutr Metab Care. 2018;21(3):168-73.
Lausman A, McCarthy FP, Walker M, Kingdom J. Screening, Diagnosis, and Management of Intrauterine Growth Restriction. J Obstet Gynaecol Can. 2012;34(1):17-28.
Stockley EL, Ting JY, Kingdom JC, et al. Intrapartum magnesium sulfate is associated with neuroprotection in growth-restricted fetuses. Am J Obstet Gynecol. 2018;219(6):606.e1-606.e8.